ArticleThe European respiratory journal2024
Rifampicin has no role in treatment of
Article in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Treatment Outcomes ofOpen forum infectious diseases · 2025Trial
- Effect of Individual Agents on Time to Culture Conversion inOpen forum infectious diseases · 2025Trial
- Macrolide-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Cytochrome P450-Mediated Metabolism of AntimycobacterialACS infectious diseases · 2026Article
- Exposure to azithromycin and the effect of co-administration of rifampicin in patients with non-tuberculous mycobacterial disease.The Journal of antimicrobial chemotherapy · 2026Article
- Inhalational therapy of pulmonary infectionActa pharmaceutica Sinica. B · 2026Article
- Impact of vitamin D deficiency on 6-month culture conversion in nontuberculous mycobacterial pulmonary disease.Scientific reports · 2026Article
- Efficacies of Sequenced Monotherapies of Mycobacterium avium Lung Infection in Mouse.The Journal of infectious diseases · 2026Article
- Genomic population structure, antimicrobial susceptibility, and clinical features ofJournal of clinical microbiology · 2026Article
- Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistantAntimicrobial agents and chemotherapy · 2026Article
- Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system.The Journal of antimicrobial chemotherapy · 2026Article
- Efficacy of drug regimens containing omadacycline in a murine model ofFrontiers in microbiology · 2026Article
- Treatment strategies forBreathe (Sheffield, England) · 2026Article
- Efficacies of sequenced monotherapies ofbioRxiv : the preprint server for biology · 2025Article
- Detection of a Mixed-Strain Infection with Drug- and Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Current and emerging treatment strategies forEwha medical journal · 2025Review
- Tolerability and efficacy of Mycobacterium avium complex pulmonary disease treatment in elderly patients.BMC pulmonary medicine · 2025Article
- Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.Pathogens & immunity · 2025Review
- Toward better cures forClinical microbiology reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.